Jacques Genest jr

List of Publications by Citations

97 papers	13,726 citations	35 h-index	110 g-index
110 ext. papers	17,242 ext. citations	6.9 avg, IF	5.99 L-index

#	Paper	IF	Citations
97	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *New England Journal of Medicine*, **2008**, 359, 2195-207	59.2	4661
96	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine*, **2017**, 377, 1119-1131	59.2	3877
95	Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2017**, 390, 1833-1842	40	634
94	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Canadian Journal of Cardiology*, **2016**, 32, 1263-1282	3.8	543
93	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet, The*, **2018**, 391, 319-328	40	430
92	Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation*, **2001**, 103, 1198-205	16.7	262
91	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 850-61	18.1	215
90	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet, The*, **2010**, 376, 333-9	40	178
89	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. *Atherosclerosis*, **2018**, 276, 98-108	3.1	172
88	Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. *BMJ Open*, **2017**, 7, e016461	3	160
87	High-density lipoproteins and endothelial function. *Circulation*, **2001**, 104, 1978-83	16.7	158
86	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). *Canadian Journal of Cardiology*, **2016**, 32, S35-65	3.8	138
85	Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. *FASEB Journal*, **2003**, 17, 512-4	0.9	130
84	Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. *Atherosclerosis*, **2013**, 226, 9-15	3.1	119
83	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. *Circulation*, **2020**, 141, 1742-1759	16.7	117
82	High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. *BBA Clinical*, **2015**, 3, 175-88		96
81	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93

80	Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. *Cmaj*, **2003**, 169, 921-4	3.5	86
79	C-reactive protein: risk factor, biomarker and/or therapeutic target?. *Canadian Journal of Cardiology* , **2010**, 26 Suppl A, 41A-44A	3.8	72
78	Canadian Cardiovascular Society position statement on familial hypercholesterolemia. *Canadian Journal of Cardiology*, **2014**, 30, 1471-81	3.8	71
77	APOE p.Leu167del mutation in familial hypercholesterolemia. *Atherosclerosis*, **2013**, 231, 218-22	3.1	67
76	Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. *Journal of Lipid Research*, **2005**, 46, 1668-77	6.3	62
75	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. *Canadian Journal of Cardiology*, **2021**, 37, 1129-1150	3.8	62
74	HDL, Atherosclerosis, and Emerging Therapies. *Cholesterol*, **2013**, 2013, 891403		59
73	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. *Canadian Journal of Cardiology*, **2018**, 34, 1553-1563	3.8	58
72	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. *Circulation*, **2017**, 135, 1819-1831	16.7	52
71	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. *Atherosclerosis*, **2011**, 219, 455-62	3.1	50
70	High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. *American Journal of Cardiology*, **2014**, 113, 249-55	3	47
69	Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. *Journal of Biological Chemistry*, **2008**, 283, 11164-75	5.4	46
68	Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. *Circulation: Cardiovascular Quality and Outcomes*, **2014**, 7, 815-27	5.8	45
67	Plasma homocysteine concentration in children with chronic renal failure. *Pediatric Nephrology*, **2001**, 16, 805-11	3.2	43
66	Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. *American Journal of Cardiology*, **2004**, 93, 848-53	3	42
65	ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. *Atherosclerosis*, **2017**, 257, 90-99	3.1	40
64	Prevention of cardiovascular ischemic events: high-risk and secondary prevention. *Circulation*, **2003**, 107, 2059-65	16.7	40
63	Simplified Canadian Definition for Familial Hypercholesterolemia. *Canadian Journal of Cardiology*, **2018**, 34, 1210-1214	3.8	36

62	Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of pre-1 HDL In Vitro. *PLoS ONE*, **2015**, 10, e0131997	3.7	35
61	Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification. *JACC Basic To Translational Science*, **2017**, 2, 358-371	8.7	34
60	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. *Clinical Chemistry*, **2018**, 64, 355-362	5.5	32
59	Reducing Vascular Calcification by Anti-IL-1 Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. *Angiology*, **2016**, 67, 157-67	2.1	31
58	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. *Canadian Journal of Cardiology*, **2017**, 33, 325-333	3.8	30
57	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A´systematic review and meta-analysis. *Journal of Clinical Lipidology*, **2019**, 13, 15-30	4.9	28
56	HDL cholesterol and ASCVD risk stratification: A debate. *Atherosclerosis*, **2019**, 283, 7-12	3.1	27
55	Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. *Clinical Chemistry*, **2014**, 60, 1380-9	5.5	27
54	The WWOX gene modulates high-density lipoprotein and lipid metabolism. *Circulation: Cardiovascular Genetics*, **2014**, 7, 491-504		26
53	Aortic calcifications in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. *American Heart Journal*, **2009**, 157, 170-6	4.9	26
52	Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. *Journal of Lipid Research*, **2011**, 52, 2043-55	6.3	23
51	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2014**, 1842, 1498-512	5	22
50	Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C]. *Atherosclerosis*, **1999**, 146, 125-31	3.1	22
49	Familial hypercholesterolemia: experience from the French-Canadian population. *Current Opinion in Lipidology*, **2018**, 29, 59-64	4.4	17
48	Approach to the diagnosis and management of lipoprotein disorders. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2009**, 16, 132-40	4	17
47	Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. *European Journal of Preventive Cardiology*, **2019**, 26, 1262-1270	3.9	16
46	Severe xanthomatosis in heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2018**, 12, 872-877	4.9	15
45	Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. *European Heart Journal*, **2018**, 39, 1194-1202	9.5	15

44	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. *Clinical Chemistry*, **2016**, 62, 428-35	5.5	15
43	Estrogen-associated severe hypertriglyceridemia with pancreatitis. *Journal of Clinical Lipidology*, **2017**, 11, 297-300	4.9	14
42	Pathological significance of lipoprotein(a) in aortic valve stenosis. *Atherosclerosis*, **2018**, 272, 168-174	3.1	14
41	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. *Atherosclerosis*, **2020**, 311, 13-19	3.1	14
40	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
39	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. *Canadian Journal of Cardiology*, **2006**, 22, 863-8	3.8	13
38	High-density lipoproteins: multifunctional vanguards of the cardiovascular system. *Expert Review of Cardiovascular Therapy*, **2004**, 2, 417-30	2.5	13
37	Genetics and prevention: a new look at high-density lipoprotein cholesterol. *Cardiology in Review*, **2002**, 10, 61-71	3.2	13
36	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. *Canadian Journal of Cardiology*, **2017**, 33, 658-665	3.8	12
35	HDLs and the pathogenesis of atherosclerosis. *Current Opinion in Cardiology*, **2018**, 33, 311-316	2.1	12
34	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. *Peptides*, **2014**, 55, 151-7	3.8	12
33	Genetics of cholesterol efflux. *Current Atherosclerosis Reports*, **2012**, 14, 235-46	6	12
32	ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. *Canadian Journal of Cardiology*, **2019**, 35, 770-781	3.8	11
31	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2019**, 13, 123-128	4.9	11
30	HDL-Mediated Cellular Cholesterol Efflux Assay Method. *Annals of Clinical and Laboratory Science*, **2015**, 45, 659-68	0.9	11
29	Treatment options for low high-density lipoproteins. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2014**, 21, 134-9	4	10
28	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. *Canadian Journal of Cardiology*, **2016**, 32, 1552-1560	3.8	10
27	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. *Atherosclerosis*, **2018**, 277, 419-424	3.1	10

26	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. *Journal of Clinical Lipidology*, **2018**, 12, 1027-1038	4.9	9
25	Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of Trypanosoma cruzi. *American Journal of Pathology*, **2014**, 184, 976-984	5.8	9
24	Anxiety, depression, and health-related quality of life in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. *Journal of Psychosomatic Research*, **2018**, 109, 32-43	4.1	8
23	Membrane microdomains and the regulation of HDL biogenesis. *Current Opinion in Lipidology*, **2018**, 29, 36-41	4.4	8
22	Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. *Angiology*, **2019**, 70, 726-736	2.1	7
21	Novel Approaches for HDL-Directed Therapies. *Current Atherosclerosis Reports*, **2017**, 19, 55	6	6
20	Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. *Current Opinion in Lipidology*, **2020**, 31, 176-181	4.4	6
19	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2632-2640	9.4	6
18	Severe hyperhomocysteinemia due to cystathionine □synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis. *Thrombosis Journal*, **2014**, 12, 30	5.6	4
17	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
16	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Qu□bec experience. *Atherosclerosis*, **2020**, 310, 54-63	3.1	4
15	The analysis by Manuel and colleagues creates controversy with headlines, not data. *Cmaj*, **2005**, 172, 1033-4; discussion 1037	3.5	3
14	Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis. *Frontiers in Pharmacology*, **2021**, 12, 679456	5.6	3
13	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. *CJC Open*, **2019**, 1, 190-197	2	2
12	The Lifelong Burden of Homozygous Familial Hypercholesterolemia. *Canadian Journal of Cardiology* , **2019**, 35, 1419.e1-1419.e4	3.8	2
11	Abstract 1696: Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early (phase I) Human Trials. *Circulation*, **2008**, 118,	16.7	2
10	Disorders of high-density lipoprotein biogenesis. *Annals of Medicine*, **2008**, 40, 39-47	1.5	1
9	New Strategies to Promote Macrophage Cholesterol Efflux.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 795868	5.4	1

List of Publications

8	Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry. *Canadian Journal of Cardiology*, **2021**,	3.8	1
7	Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. *Journal of the American Heart Association*, **2021**, 10, e019286	6	1
6	Dj1 deficiency protects against atherosclerosis with anti-inflammatory response in macrophages. *Scientific Reports*, **2021**, 11, 4723	4.9	1
5	Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.. *Communications Biology*, **2022**, 5, 132	6.7	0
4	Genetics of High-Density Lipoproteins **2007**, 465-490		
3	The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention. *Current Pediatric Reviews*, **2017**, 13, 260-264	2.8	
2	Novel insights on high-density lipoprotein in coronary heart disease. *International Journal of Clinical Practice, Supplement*, **2002**, 17-22		
1	Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?. *Canadian Journal of Cardiology*, **2004**, 20 Suppl B, 89B-92B	3.8	